ClinicalTrials.gg
CompletedNCT00694044Updated Jun 2, 2009

Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

A Phase 1 interventional study of varenicline and varenicline in Healthy and Non-Smoking, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-06-02.

Sponsored by Pfizer · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Study summary

  1. Characterize the tolerability and safety of repeated doses of varenicline in healthy non-smoking elderly subjects.
  2. Describe the steady state pharmacokinetics of varenicline in healthy non-smoking elderly subjects.
  3. Evaluate the potential effects of repeat doses of varenicline on cognition in healtly non-smoking elderly subjects.
02

Conditions studied

  • Healthy
  • Non-Smoking

Keywords

  • Safety, Tolerability, Pharmacokinetics, Cognition
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy, Elderly (65-85 years inclusive), Non-smoker

Exclusion criteria

Exclusion Criteria:

Creatinine Clearnace \< 30 ml/min, Evidence or history of , unstable diseases

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Weekly titration

    Drug: varenicline

  • Active comparator
    Two Week QD

    Drug: varenicline

  • Active comparator
    Two Week BID

    Drug: varenicline

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days

    Also known as: Champix, Chantix

  • 0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days

    Also known as: Champix, Chantix

  • 0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days

    Also known as: Champix, Chantix

  • DrugPlacebo

    Placebo for 21 days

06

What researchers measure

Primary outcomes

  1. Tolerability and safety (adverse events, electrocardiogram, vital signs, clinical safety labs, self reported nausea visual analogue scales)

    Time frame: 21 days

  2. Steady state pharmacokinetics

    Time frame: 21 days

  3. Effects on cognition (computerized battery of cognitive tests)

    Time frame: 21 days

Secondary outcomes

  1. No secondary outcomes.

    Time frame: Time frame n/a

07

Study locations

2 sites
  • Pfizer Investigational Site
    Miami, Florida 33169, United States
  • Pfizer Investigational Site
    Orlando, Florida 32809, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2008
First posted
Jun 10, 2008
Start
Apr 2008
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Last update
Jun 2, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00694044
Lead sponsor
Pfizer
First posted
Jun 10, 2008
Start date
Apr 2008
Primary completion
Jun 2008
Completion
Jun 2008
Last update
Jun 2, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion